Loading clinical trials...
Loading clinical trials...
This Phase IIb study is designed to assess whether 3 doses of AFQ056 are safe and effective in treating the behavioral symptoms of Fragile X Syndrome.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT06560242 · Fragile X Syndrome
NCT06139172 · Telomeric 22Q13 Monosomy Syndrome, Tuberous Sclerosis, and more
NCT06677866 · Fragile X Syndrome (FXS), Autism Spectrum Disorder
NCT05418049 · Fragile X Syndrome
NCT07439510 · Fragile X Syndrome (FXS)
Novartis Investigative Site
Sacramento, California
Novartis Investigative Site
Decatur, Georgia
Novartis Investigative Site
Chicago, Illinois
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions